{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:01:38Z","timestamp":1767913298103,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The newly developed mRNA-based COVID-19 vaccines can provoke anaphylaxis, possibly induced by polyethylene glycol (PEG) contained in the vaccine. The management of persons with a history of PEG allergy or with a suspected allergic reaction after the first dose remains to be defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this real-life study, we defined two cohorts of individuals: one pre-vaccination including 187 individuals with high-risk profiles for developing anaphylaxis and a second post-vaccination including 87 individuals with suspected allergic reactions after the COVID-19 mRNA vaccine. Upon negative skin test with an mRNA vaccine, a two-step (10\u201390%) vaccination protocol was performed. Positive skin tests were confirmed with the basophil activation test (BAT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 604,267 doses of vaccine, 87 suspected allergic reactions (5 after the booster) were reported to our division for further investigations: 18\/87 (21%) were consistent with anaphylaxis, 78\/87 (90%) were female, and 47\/87 (54%) received the BNT162b2 mRNA vaccine. Vaccine skin tests were negative in 96% and 76% of the pre- and post-vaccination cohorts, respectively. A two-step vaccination was tolerated in 232\/236 (98%) of individuals with negative tests. Four individuals experienced isolated asthmatic reactions during the two-step challenge. Vaccine-positive skin tests were consistently confirmed by BAT; CD63 and CD203c expression was selectively inhibited with ibrutinib, suggesting an IgE-dependent mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sensitization to SARS-CoV-2 mRNA vaccines can be detected with intradermal testing. Significantly more individuals were sensitized to mRNA vaccines in the post-vaccination cohort. A two-step 10\u201390%-vaccination protocol can be safely administered upon negative skin testing.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2022.818049","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:19:00Z","timestamp":1654067940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Intradermal Testing With COVID-19 mRNA Vaccines Predicts Tolerance"],"prefix":"10.3389","volume":"3","author":[{"given":"Florian","family":"Stehlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Mahdi-Aljedani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loris","family":"Canton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Monzambani-Banderet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Miauton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kammermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Meylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Harr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick D.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/all.14711","article-title":"Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol [editorial]","volume":"76","author":"Cabanillas","year":"2020","journal-title":"Allergy."},{"key":"B2","volume-title":"Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020\u2013January 18","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2122255","DOI":"10.1001\/jamanetworkopen.2021.22255","article-title":"Prevalence of allergic reactions after pfizer-BioNTech cOVID-19 vaccination among adults with high allergy risk","volume":"4","author":"Shavit","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to sARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-Analysis, gRADE assessment, and international consensus approach","volume":"21","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.anai.2021.03.012","article-title":"Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report.[letter]","volume":"126","author":"Pitlick","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the pfizer\/BioNTech mRNA cOVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaip.2020.09.029","article-title":"Polyethylene glycol-Induced systemic allergic reactions (anaphylaxis)","volume":"9","author":"Sellaturay","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/all.12437","article-title":"Anaphylaxis: guidelines from the european academy of allergy and clinical immunology","volume":"69","author":"Muraro","year":"2014","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/all.12441","article-title":"EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community","volume":"69","author":"Muraro","year":"2014","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guideline: anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2021","journal-title":"Allergy."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block igE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.jaip.2021.04.025","volume":"9","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA cOVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1007\/s11606-021-07015-w","article-title":"Delayed hypersensitivity reactions following first dose of the sARS-CoV2 mRNA vaccines","volume":"36","author":"Xu","year":"2021","journal-title":"J Gen Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","article-title":"Incidence of cutaneous reactions after messenger rNA cOVID-19 vaccines.[letter]","volume":"157","author":"Robinson","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after moderna and pfizer cOVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-Dose mRNA cOVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jaip.2020.11.011","article-title":"Anti-PEG igE in anaphylaxis associated with polyethylene glycol","volume":"4","author":"Zhou","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2021.05.020","article-title":"Optimizing investigation of suspected allergy to polyethylene glycols","volume":"149","author":"Bruusgaard-Mouritsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13223-019-0327-4","article-title":"Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary","volume":"15","author":"Jover Cerd\u00e1","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/j.1398-9995.2006.01083.x","article-title":"Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tablets","volume":"61","author":"Hyry","year":"2006","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.anai.2011.08.008","article-title":"Macrogol hypersensitivity in multiple drug allergy","volume":"107","author":"Bommarito","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1398-9995.2007.01610.x","article-title":"Usefulness of oral macrogol challenge in anaphylaxis after intra-articular injection of corticosteroid preparation","volume":"63","author":"Sohy","year":"2008","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.anai.2021.03.024","article-title":"Misdiagnosis of systemic allergic reactions to mRNA cOVID-19 vaccines","volume":"127","author":"Kelso","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/all.15241","article-title":"Allergies and COVID-19 vaccines: an ENDA\/EAACI position paper","author":"Barbaud","year":"2022","journal-title":"Allergy."},{"key":"B31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2125524","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 Vaccines with confirmatory testing in a US Regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-Coated liposomes: roles of anti-PEG igM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"B34","doi-asserted-by":"publisher","first-page":"106678","DOI":"10.1016\/j.vascn.2020.106678","article-title":"Antibodies against polyethylene glycol in human blood: a literature review","volume":"102","author":"Hong","year":"2020","journal-title":"J Pharmacol Toxicol Methods"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/all.15148","article-title":"The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine","author":"Labella","year":"2021","journal-title":"Allergy."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.8515","article-title":"Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis","author":"Chu","year":"2022","journal-title":"JAMA Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"eabi8452","DOI":"10.1126\/scitranslmed.abi8452","article-title":"A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma","volume":"13","author":"Fenwick","year":"2021","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jaip.2021.05.031","article-title":"Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination","volume":"9","author":"Robinson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.818049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:25:09Z","timestamp":1680258309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.818049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":39,"alternative-id":["10.3389\/falgy.2022.818049"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2022.818049","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"818049"}}